RxDoctor Payments Data

Patrick Swanson, MD

Psychosomatic Medicine · Cincinnati, OHNPI 1891900577

Payments from drug & device makers

$472in general payments, 2019–2025

Across 22 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$210
  • Johnson & Johnson$69
  • Vanda Pharmaceuticals Inc.$46
  • Lundbeck LLC$32
  • Soleno Therapeutics, Inc.$24
  • Alkermes, Inc.$23
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few psychosomatic medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$17,107
Medicare patients
78
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$267,370
Invega SustennaPaliperidone Palmitate24$72,841
RexultiBrexpiprazole42$59,673
Divalproex Sodium ErDivalproex Sodium272$31,228
CaplytaLumateperone Tosylate17$27,098
Aripiprazole184$26,534
LybalviOlanzapine/Samidorphan Malate15$25,163
Asenapine Maleate58$22,914
VraylarCariprazine Hcl13$19,715
Clozapine154$17,419
Ziprasidone Hcl147$12,353
Quetiapine Fumarate187$7,310
Trazodone Hcl343$7,018
Chlorpromazine Hcl32$6,027
Vilazodone Hcl24$5,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$210$267,37031 claims
Johnson & JohnsonInvega Sustenna$69$72,84124 claims
Alkermes, Inc.Lybalvi$23$25,16315 claims
AbbVieVraylar$19$19,71513 claims
Teva Pharmaceuticals USA, Inc.Loxapine$16$2,51744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other psychosomatic medicine in Cincinnati

Where these figures come from

Is this you, or does something look wrong? →